ESCRS - Laser or ultrasound in cataract surgery?

Laser or ultrasound in cataract surgery?

Laser or ultrasound in cataract surgery?
Roibeard O’hEineachain
Roibeard O’hEineachain
Published: Monday, December 5, 2016
1185579_63423610   Femtosecond laser-assisted cataract surgery (FLACS) provides better visual outcomes with less trauma to the eye compared to conventional cataract surgery, according to a meta-analysis of peer-reviewed studies presented at the XXXIV Congress of the ESCRS in Copenhagen, Denmark. The analysis showed that FLACS performed significantly better than conventional surgery in terms of uncorrected visual acuity, corneal endothelial cell loss and effective phaco time (EPT), and that it posed no additional dangers to the eye apart from a slightly but significantly higher incidence of anterior capsule rupture, reported Thomas Kohnen MD, PhD, Goethe University, Frankfurt, Germany. “FLACS has a comparable advantage and disadvantage profile to conventional cataract surgery. However, FLACS appears to be superior overall,” he added. Prof Kohnen and his associates included in their meta-analysis 38 peer-reviewed prospective and retrospective studies published from April 2015 to March 2016. The studies were identified through a systematic review of MEDLINE, The Cochrane Library and Embase. In total, the studies included 8,198 eyes that underwent FLACS and 7,684 eyes that underwent conventional cataract surgery with ultrasound phacoemulsification and manual incisions and capsulotomies. All of the studies compared the two cataract surgery approaches, each recording their own sets of parameters. The researchers found that mean uncorrected visual acuity was significantly better in FLACS-treated eyes than in conventionally treated eyes, both overall and in five of seven studies involving a total of 2,215 eyes (p<0.01). Best corrected visual acuity was also better during the first week (p=0.001), but not after the first month. Furthermore, in most of the trials, mean EPT was several times lower in the FLACS groups. That is, in 11 trials involving a total of 609 eyes, mean EPT ranged from 0 seconds to 5.6 seconds among FLACS-treated eyes, and from 0.12 seconds to 14.24 among conventionally treated eyes. LOWER CENTRAL CORNEAL THICKNESS Endothelial cell loss after six months was significantly lower in the FLACS-treated patients, both overall and in five of seven trials, which together involved a total of 833 eyes. The FLACS-treated eyes also had significantly lower central corneal thickness one day and one month after surgery compared to conventionally treated eyes. FLACS also did not appear to endanger the posterior segment to any greater extent than conventional cataract surgery. For example, posterior capsule rupture occurred with similar frequency with the two treatments, as was the case with macular oedema and increased intraocular pressure within the first 24 hours of surgery. Thomas Kohnen: kohnen@em.uni-frankfurt.de
Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...